The trial compared Zyvox to vancomycin, oxacillin, or dicloxacillin (comparator antibiotics) in the treatment of seriously ill patients with intravascular catheter-related bloodstream infections including those with catheter-site infections.
Soliris is the first therapy approved for paroxysmal nocturnal hemoglobinuria (PNH), a rare, disabling and life-threatening blood disorder defined by chronic red blood cell destruction, or hemolysis, the
The drug did not show a difference from placebo in the study, although the company said that it did achieve a reduction in the composite of “hard” atherosclerotic
The US-based company said that more than 73% of patients receiving injections of hyaluronic acid during treatment for osteoarthritis experienced better pain relief to standard treatment. The study,
Preliminary data showed that the two different erdosteine treatment groups did not seem to break statistically from placebo. The company said that further analyses will continue during the
In addition to the management departures, the company announced that its development partnership with Roche for an AIDS drug had been terminated. However, its agreement with the drug
Emergent has signed a license agreement with Coley for the use of the vaccine and intends to utilize it the development of new anthrax vaccines. Financial terms of
A Canadian study to determine which inhaler regimen would best prevent a bout of worsening symptoms in chronic obstructive pulmonary disease (COPD) found that there was not much
Professor David Lambert, who has been involved in the development of the drug in collaboration with Dr Girolamo Calo in Ferrara, Italy, believes that the new drug, UFP-101,
The primary objective of the studies is to evaluate the safety and tolerability of treatment with Amigal, while the secondary objective is to evaluate certain pharmacodynamic measures of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.